Curated News
By: NewsRamp Editorial Staff
October 27, 2025
Nutriband Founder Returns as CEO to Lead Fentanyl Patch Development
TLDR
- Nutriband's founder returns as CEO to lead AVERSA Fentanyl development, targeting $80-200M annual US sales with patented abuse-deterrent technology in 46 countries.
- Nutriband's AVERSA technology incorporates abuse-deterrent features into transdermal patches to prevent misuse, with an NDA filing planned for 2026 after final development.
- AVERSA Fentanyl's abuse-deterrent design helps prevent opioid misuse and accidental exposure, creating safer pain management options for patients and communities.
- Nutriband's patented AVERSA technology transforms transdermal patches into abuse-deterrent systems protected across 46 countries including the US, Europe, and Japan.
Impact - Why it Matters
The development of abuse-deterrent opioid formulations represents a critical advancement in addressing the ongoing opioid crisis that has devastated communities worldwide. AVERSA Fentanyl's technology could significantly reduce the potential for misuse and accidental exposure to powerful opioids, potentially saving lives and reducing addiction rates. For patients who genuinely need potent pain management, this technology offers safer access to necessary medications while minimizing the risk of diversion and abuse. The successful development and approval of such technologies could set new standards for opioid safety and influence regulatory requirements across the pharmaceutical industry, ultimately benefiting public health and safety while providing legitimate pain patients with more secure treatment options.
Summary
Nutriband Inc. (NASDAQ: NTRB) has announced a significant leadership transition as company founder Gareth Sheridan resumes his role as CEO, effective immediately. This change follows a temporary period where Co-Founder and Chairman Serguei Melnik served in the position. Sheridan's return comes at a critical juncture as he will lead the company through its final 2025 development framework toward an expected 2026 New Drug Application (NDA) filing for AVERSA Fentanyl, the company's flagship abuse-deterrent opioid patch. This leadership stability is crucial for navigating the complex regulatory pathway and maintaining momentum in the pharmaceutical development process.
The company's primary focus remains on AVERSA Fentanyl, an innovative transdermal patch designed specifically to deter misuse and accidental exposure to the potent opioid. Market projections indicate substantial commercial potential, with estimated peak annual U.S. sales ranging between $80 million and $200 million. The underlying AVERSA technology represents a significant advancement in pharmaceutical safety, as it can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology enjoys robust intellectual property protection with patents secured in 46 countries, including major pharmaceutical markets like the United States, Europe, and Japan, providing the company with substantial competitive advantages and market exclusivity potential.
As part of the broader communications strategy, the news was distributed through InvestorWire, which operates within the Dynamic Brand Portfolio of IBN, ensuring comprehensive market coverage through advanced wire-grade press release syndication and extensive media distribution networks. The company maintains an active presence through its corporate website and dedicated newsroom, providing ongoing updates to investors and stakeholders about development progress and corporate milestones as they work toward their 2026 regulatory submission target.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Founder Returns as CEO to Lead Fentanyl Patch Development
